FDA Approves First Photodynamic Therapy for Basal Cell Carcinoma
September 17, 2026
The U.S. Food and Drug Administration has approved aminolevulinic acid hydrochloride 10% topical gel (Ameluz), used together with red light…
SkylineDx to Present Data on Precision Molecular Diagnostics Advances in Cutaneous Squamous Cell Carcinoma at 22nd EADO Congress
April 23, 2026
New gene-signature for cutaneous squamous cell carcinoma (CSCC) demonstrates ability to identify a subset of patients with higher risk of developing…
Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation
October 8, 2025
The first and only FDA-approved immunotherapy for this patient population October 8, 2025 (Sacramento, California) The FDA has approved the…
Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
December 16, 2024
The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
Recent Posts
Sep. 23, 2026
Cutaneous Squamous Cell Carcinoma Explained: Watch Our New 3-Part Animated Video Series
Sep. 17, 2026
FDA Approves First Photodynamic Therapy for Basal Cell Carcinoma
Sep. 16, 2026
Basal Cell Carcinoma Explained: Watch Our New 3-Part Animated Video Series
Sep. 01, 2026
Under the Same Sun
Jun. 29, 2026